A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma

Daisuke Aoki, Noriyuki Katsumata, Toru Nakanishi, Junzo Kigawa, Keiichi Fujiwara, Kazuhiro Takehara, Shoji Kamiura, Masamichi Hiura, Masayuki Hatae, Toru Sugiyama, Kazunori Ochiai, Kiichiro Noda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: This Phase II study was carried out to investigate the efficacy, safety and pharmacokinetics of topotecan in Japanese patients with relapsed ovarian carcinoma. Methods: Patients with relapsed ovarian carcinoma after having received one regimen containing platinum-based chemotherapy were eligible for this study. Topotecan was administered at 1.2 mg/m2/day for five consecutive days, repeated every 3 weeks. Results: Seventy-two patients were enrolled in the study. The response rate was 28.2% (95% confidence interval, 18.1-40.1%). Signs of myelosuppression, such as neutropenia (Grade 3, 12.5%; Grade 4, 83.3%), thrombocytopenia (Grade 3, 36.2%; Grade 4, 4.2%) and decreased hemoglobin (Grade 3, 36.1%; Grade 4, 11.1%), were the most common hematological toxicities. Grade 3 febrile neutropenia occurred in 5 (6.9%) patients. There was little intraindividual or interindividual variability in the pharmacokinetics of topotecan. Conclusions: Topotecan at 1.2 mg/m2/day is an effective and tolerable therapeutic option for Japanese patients with relapsed ovarian carcinoma.

Original languageEnglish
Article numberhyq192
Pages (from-to)320-327
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume41
Issue number3
DOIs
Publication statusPublished - 2011 Mar

Fingerprint

Topotecan
Phase II Clinical Trials
Carcinoma
Pharmacokinetics
Febrile Neutropenia
Neutropenia
Platinum
Hemoglobins
Confidence Intervals
Safety
Drug Therapy

Keywords

  • Clinical trial
  • Pharmacokinetics
  • Phase II
  • Relapsed ovarian carcinoma
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Aoki, D., Katsumata, N., Nakanishi, T., Kigawa, J., Fujiwara, K., Takehara, K., ... Noda, K. (2011). A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. Japanese Journal of Clinical Oncology, 41(3), 320-327. [hyq192]. https://doi.org/10.1093/jjco/hyq192

A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. / Aoki, Daisuke; Katsumata, Noriyuki; Nakanishi, Toru; Kigawa, Junzo; Fujiwara, Keiichi; Takehara, Kazuhiro; Kamiura, Shoji; Hiura, Masamichi; Hatae, Masayuki; Sugiyama, Toru; Ochiai, Kazunori; Noda, Kiichiro.

In: Japanese Journal of Clinical Oncology, Vol. 41, No. 3, hyq192, 03.2011, p. 320-327.

Research output: Contribution to journalArticle

Aoki, D, Katsumata, N, Nakanishi, T, Kigawa, J, Fujiwara, K, Takehara, K, Kamiura, S, Hiura, M, Hatae, M, Sugiyama, T, Ochiai, K & Noda, K 2011, 'A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma', Japanese Journal of Clinical Oncology, vol. 41, no. 3, hyq192, pp. 320-327. https://doi.org/10.1093/jjco/hyq192
Aoki, Daisuke ; Katsumata, Noriyuki ; Nakanishi, Toru ; Kigawa, Junzo ; Fujiwara, Keiichi ; Takehara, Kazuhiro ; Kamiura, Shoji ; Hiura, Masamichi ; Hatae, Masayuki ; Sugiyama, Toru ; Ochiai, Kazunori ; Noda, Kiichiro. / A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. In: Japanese Journal of Clinical Oncology. 2011 ; Vol. 41, No. 3. pp. 320-327.
@article{c027d660e58646949032006a4e3daf1c,
title = "A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma",
abstract = "Objective: This Phase II study was carried out to investigate the efficacy, safety and pharmacokinetics of topotecan in Japanese patients with relapsed ovarian carcinoma. Methods: Patients with relapsed ovarian carcinoma after having received one regimen containing platinum-based chemotherapy were eligible for this study. Topotecan was administered at 1.2 mg/m2/day for five consecutive days, repeated every 3 weeks. Results: Seventy-two patients were enrolled in the study. The response rate was 28.2{\%} (95{\%} confidence interval, 18.1-40.1{\%}). Signs of myelosuppression, such as neutropenia (Grade 3, 12.5{\%}; Grade 4, 83.3{\%}), thrombocytopenia (Grade 3, 36.2{\%}; Grade 4, 4.2{\%}) and decreased hemoglobin (Grade 3, 36.1{\%}; Grade 4, 11.1{\%}), were the most common hematological toxicities. Grade 3 febrile neutropenia occurred in 5 (6.9{\%}) patients. There was little intraindividual or interindividual variability in the pharmacokinetics of topotecan. Conclusions: Topotecan at 1.2 mg/m2/day is an effective and tolerable therapeutic option for Japanese patients with relapsed ovarian carcinoma.",
keywords = "Clinical trial, Pharmacokinetics, Phase II, Relapsed ovarian carcinoma, Topotecan",
author = "Daisuke Aoki and Noriyuki Katsumata and Toru Nakanishi and Junzo Kigawa and Keiichi Fujiwara and Kazuhiro Takehara and Shoji Kamiura and Masamichi Hiura and Masayuki Hatae and Toru Sugiyama and Kazunori Ochiai and Kiichiro Noda",
year = "2011",
month = "3",
doi = "10.1093/jjco/hyq192",
language = "English",
volume = "41",
pages = "320--327",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma

AU - Aoki, Daisuke

AU - Katsumata, Noriyuki

AU - Nakanishi, Toru

AU - Kigawa, Junzo

AU - Fujiwara, Keiichi

AU - Takehara, Kazuhiro

AU - Kamiura, Shoji

AU - Hiura, Masamichi

AU - Hatae, Masayuki

AU - Sugiyama, Toru

AU - Ochiai, Kazunori

AU - Noda, Kiichiro

PY - 2011/3

Y1 - 2011/3

N2 - Objective: This Phase II study was carried out to investigate the efficacy, safety and pharmacokinetics of topotecan in Japanese patients with relapsed ovarian carcinoma. Methods: Patients with relapsed ovarian carcinoma after having received one regimen containing platinum-based chemotherapy were eligible for this study. Topotecan was administered at 1.2 mg/m2/day for five consecutive days, repeated every 3 weeks. Results: Seventy-two patients were enrolled in the study. The response rate was 28.2% (95% confidence interval, 18.1-40.1%). Signs of myelosuppression, such as neutropenia (Grade 3, 12.5%; Grade 4, 83.3%), thrombocytopenia (Grade 3, 36.2%; Grade 4, 4.2%) and decreased hemoglobin (Grade 3, 36.1%; Grade 4, 11.1%), were the most common hematological toxicities. Grade 3 febrile neutropenia occurred in 5 (6.9%) patients. There was little intraindividual or interindividual variability in the pharmacokinetics of topotecan. Conclusions: Topotecan at 1.2 mg/m2/day is an effective and tolerable therapeutic option for Japanese patients with relapsed ovarian carcinoma.

AB - Objective: This Phase II study was carried out to investigate the efficacy, safety and pharmacokinetics of topotecan in Japanese patients with relapsed ovarian carcinoma. Methods: Patients with relapsed ovarian carcinoma after having received one regimen containing platinum-based chemotherapy were eligible for this study. Topotecan was administered at 1.2 mg/m2/day for five consecutive days, repeated every 3 weeks. Results: Seventy-two patients were enrolled in the study. The response rate was 28.2% (95% confidence interval, 18.1-40.1%). Signs of myelosuppression, such as neutropenia (Grade 3, 12.5%; Grade 4, 83.3%), thrombocytopenia (Grade 3, 36.2%; Grade 4, 4.2%) and decreased hemoglobin (Grade 3, 36.1%; Grade 4, 11.1%), were the most common hematological toxicities. Grade 3 febrile neutropenia occurred in 5 (6.9%) patients. There was little intraindividual or interindividual variability in the pharmacokinetics of topotecan. Conclusions: Topotecan at 1.2 mg/m2/day is an effective and tolerable therapeutic option for Japanese patients with relapsed ovarian carcinoma.

KW - Clinical trial

KW - Pharmacokinetics

KW - Phase II

KW - Relapsed ovarian carcinoma

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=79952399526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952399526&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyq192

DO - 10.1093/jjco/hyq192

M3 - Article

C2 - 20974678

AN - SCOPUS:79952399526

VL - 41

SP - 320

EP - 327

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 3

M1 - hyq192

ER -